NHS to save £300 million by switching to Humira biosimilars

NHS to save £300 million by switching to Humira biosimilars

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of AbbVie’s best-selling anti-inflammatory drug Humira (adalimumab), bringing the current annual total spent on the drug down by 75%.

The saving is the biggest saving in NHS history from a single drug negotiation and comes in at twice as much as previous estimates. The organisation said that the savings would be enough to pay for 11,700 more community nurses or 19,800 more breast cancer treatments.

read more

Original Article: NHS to save £300 million by switching to Humira biosimilars

More From BioPortfolio on "NHS to save £300 million by switching to Humira biosimilars"